[ad_1]
The Sars-CoV-2 vaccines, which are about to be approved, have been tested in tens of thousands of people and have comparable effectiveness to other vaccines, experts told reporters Thursday. They would also be suitable for older people with accompanying illnesses (comorbidities).
Pregnant women, people with cancer, people with compromised immune systems and children were not included in clinical trials and should not be vaccinated, they said.
“Vaccines are a preventive measure and are given to healthy people. Therefore, the requirements for clinical studies are particularly high and include more than 10,000 test people to get really good data,” says Bettina Isnardy of Sanofi-Aventis, Austria.
With other therapies, sometimes only “numbers in the thousand range” would be needed. This would give you good evidence that vaccines are effective and safe.
At about 95 percent effective, the vaccine candidates would be in the range of other common vaccines, explained Renee Gallo-Daniel of the Austrian Association of Vaccine Manufacturers (ÖVIH), which organized the event online.
The companies BioNTech and Pfizer reported 95 percent effectiveness for their vaccine, Moderna for their crown vaccine 94.5 percent. TBE (tick vaccination) vaccine reaches 95 to 99 percent, HPV (human papillomavirus) vaccination 92 to 100 percent, and rotavirus vaccines (which cause dangerous diarrheal diseases in children) reach 70 to 90 percent.
Pregnant women and immunodeficient patients should not be vaccinated.
“The information on the candidate vaccines is the results of interim analysis, and after the approval process you will know what the actual efficacy figures look like,” he said.
Well-advanced Sars-CoV-2 vaccines would also be suitable for people who have already had a coronavirus infection with clinical symptoms, according to AstraZeneca’s Botond Ponner.
The studies also included subjects who had survived coronavirus infections, as well as people with well-controlled comorbidities, for example, older people with cardiovascular disease and HIV-positive people. Therefore, you could also get vaccinated.
“However, due to safety concerns, the vaccines have not been tested in pregnant women, patients with immunodeficiency, cancer or a tendency to bleed, so they should not be vaccinated,” he said. However, this would probably also be specified by the authorities in approvals, says Christian Taucher of the vaccine company Valneva Austria.
“Since the focus of the studies so far has been on adults, it can be assumed that the first approvals will only affect adults,” Gallo-Daniel said: “Later, there is a high probability that children will also be included in the studies. “
The method of using mRNA (messenger RNA) as a vaccine is not as new as is often rumored, said Andreas Wagner of Polymun Scientific Immunobiological Research: “There are definitely mRNA vaccines against influenza and rabies in human studies.”
However, these vaccines are not yet approved.
